• SPX
  • $5,734.75
  • 0.39 %
  • $22.06
  • DJI
  • $41,898.30
  • 0.25 %
  • $103.69
  • N225
  • $38,474.90
  • 1.11 %
  • $421.23
  • FTSE
  • $8,158.09
  • -0.32 %
  • -$26.15
  • IXIC
  • $18,274.91
  • 0.52 %
  • $94.93
NextCure, Inc. (NXTC) Stock Price, News & Analysis

NextCure, Inc. (NXTC) Stock Price, News & Analysis

Currency in USD Disclaimer

$1.35

$0.04

(2.88%)

Day's range
$1.35
Day's range
$1.35
50-day range
$1.27
Day's range
$1.65
  • Country: US
  • ISIN: US65343E1082
52 wk range
$1.03
Day's range
$2.57
  • CEO: Mr. Michael S. Richman MSBA
  • Website: Visit Site


We are preparing, please wait

Analyst Ratings

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

Stock Score/grades

The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company

  • Altman Z Score -4.63
  • Piotroski Score 3.00
  • Grade Buy
  • Symbol (NXTC)
  • Company NextCure, Inc.
  • Price $1.35
  • Changes Percentage (2.88%)
  • Change $0.04
  • Day Low $1.35
  • Day High $1.35
  • Year High $2.57

NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate is NC318, which is in Phase II clinical trials for the treatment of advanced or metastatic solid tumors. The company is also developing NC410, which is in Phase I for novel immunomedicine designed to block immune suppression mediated by an immune modulator called Leukocyte-Associated Immunoglobulin-like Receptor 1; NC762, an immunomedicine targeting a molecule called human B7 homolog 4 protein, or B7-H4; and NC525, a novel LAIR-1 antibody which is in Preclinical trails that targets acute myeloid leukemia, blast cells, and leukemic stem cells. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules. The company has a license agreement with Yale University. NextCure, Inc. was incorporated in 2015 and is headquartered in Beltsville, Maryland.

  • Last Earnings
  • Ex-Dividend for 5/16 Dividend
  • Dividend Payable
  • Today N/A
  • Next Earnings (Estimated) 11/04/2024
  • Fiscal Year End N/A

  • Average Stock Price Target $3.00
  • High Stock Price Target $3.00
  • Low Stock Price Target $3.00
  • Potential Upside/Downside N/A
  • Consensus Rating Sell
  • Rating Score (0-4) N/A
  • Research Coverage N/A

  • EPS (Most Recent Fiscal Year) -$2.28
  • Trailing P/E Ratio -0.61
  • Forward P/E Ratio -0.61
  • P/E Growth -0.61
  • Net Income $-62,723,000

Income Statement

Quarterly

Annual

Enter your phone number to get Breaking News Updates

Stay ahead with instant updates! Enter your phone number for breaking news alerts, ensuring you're always in the know with the latest developments.


We are preparing, please wait

Portfolio Sync Solutions

Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced

GET STARTED
Portfolio Sync Solutions
×
New Alert

Select an alert type

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.

New Alert

Setup alert

×

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.

×

Log In


or

download app using google store Continue with Google download app using apple Continue with Apple

Email Verification

An email with a verification code has been sent to your email address.

Welcome to Stocks.News!

Create Your Account

Email Verification

An email with a verification code has been sent to your email address.